LL-37

Overview

LL-37 is a naturally occurring antimicrobial peptide and the only member of the cathelicidin family found in humans. It is a key part of the innate immune system, the body's fast, general-purpose first line of defense, and is produced by immune cells and barrier tissues such as the skin. It plays roles in killing microbes and supporting wound healing.

LL-37 is endogenous, meaning the body makes it naturally; it is not an approved drug and is not a conventional supplement. Research interest centers on harnessing its antimicrobial and healing properties, but it is genuinely dual-edged: while it defends against infection, abnormal LL-37 activity is also implicated in inflammatory and autoimmune conditions.

This complexity is central to understanding LL-37. It is not simply a beneficial healing molecule; the same peptide that protects tissues has also been linked to diseases such as psoriasis, rosacea, lupus, and to aspects of cancer biology. Any discussion of it must hold both sides of this balance honestly rather than presenting it as a straightforward therapeutic.

How it works

LL-37 has several overlapping functions. Its classic role is direct antimicrobial action: the peptide is attracted to the membranes of bacteria, fungi, and some viruses, where it disrupts and punctures those membranes, killing the microbe. This makes it an important broad first-line defender at sites like the skin and airways.

Beyond killing microbes, LL-37 acts as a signaling molecule. It helps recruit immune cells to sites of infection, modulates inflammation, and promotes processes involved in wound healing, such as the formation of new blood vessels and the migration of skin cells to close wounds.

The same properties explain its dark side. LL-37 can bind the body's own DNA and RNA released from damaged cells, and these complexes can wrongly trigger immune responses, helping to drive chronic inflammation. This mechanism links LL-37 to autoimmune and inflammatory skin diseases, and its effects on cell growth and blood vessel formation can, in some contexts, support tumor biology rather than protect against it.

Research & evidence

LL-37 is a heavily studied molecule in basic immunology research. A large body of laboratory and animal work characterizes its antimicrobial activity, its role in wound healing, and its involvement in inflammation. This research has made it a target of interest for developing new infection-fighting and tissue-repair strategies, especially amid concerns about antibiotic resistance.

At the same time, research has firmly tied dysregulated LL-37 to disease. Elevated or misdirected LL-37 activity is implicated in psoriasis, rosacea, and lupus, where it contributes to harmful chronic inflammation, and studies have explored complex, context-dependent roles in various cancers.

The practical reality is that there are no established, approved LL-37 therapies for consumers. The research is rich and scientifically important, but it underscores how difficult this peptide is to translate into a safe treatment precisely because its beneficial and harmful effects are two faces of the same biology. Honest framing means acknowledging both the promise and the documented risks.

Safety & legal status

LL-37 is a natural component of the human body rather than an approved medicine, and there are no FDA-approved LL-37 drugs or supplements for consumer use. Synthetic versions sold as research chemicals are unregulated, with no assurance of purity or safety, and self-administration is not supported by adequate human safety data.

The most important safety consideration is biological rather than regulatory: because LL-37 is dual-edged, increasing its activity is not inherently safe. It is implicated in inflammatory and autoimmune skin diseases and has context-dependent links to cancer, so the assumption that more of a natural defense peptide must be beneficial is not supported by the evidence.

This content is educational only and is not medical advice or a usage protocol. LL-37 illustrates why endogenous molecules cannot be treated as casual supplements. Anyone interested in immune function, wound healing, or related skin conditions should work with qualified medical professionals rather than experimenting with an unregulated and genuinely double-edged peptide.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012. Peer-reviewed study
2. Ramos R, Silva JP, Rodrigues AC, et al. Wound healing activity of the human antimicrobial peptide LL37. Peptides. 2011. Peer-reviewed study
3. Piktel E, Niemirowicz K, Wnorowska U, et al. The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz). 2016. Peer-reviewed study
4. Otte JM, Zdebik AE, Brand S, et al. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul Pept. 2009. Peer-reviewed study
5. Leite ML, Duque HM, Rodrigues GR, et al. The LL-37 domain: A clue to cathelicidin immunomodulatory response?. Peptides. 2023. Peer-reviewed study
6. Chinipardaz Z, Zhong JM, Yang S. Regulation of LL-37 in Bone and Periodontium Regeneration. Life (Basel). 2022. Peer-reviewed study